Newsroom

CHICAGO--(BUSINESS WIRE)--TechNexus Venture Collaborative launches SecondWave to unlock strategic value in corporate venture portfolios left without active governance....

LONDON & NEW YORK--(BUSINESS WIRE)--Pantheon, a leading global private markets investor with approximately $84bn in AUM, today announced the final close of the Pantheon Global Co-Investment Opportunities Fund VI (PGCO VI) and related vehicles. At $3.2bn, the Fund is Pantheon’s largest program raised for its dedicated co-investment strategy. Since its inception as a dedicated strategy in 2009, PGCO VI has been a core component of Pantheon's $41bn1 private equity platform, providing investors wit...

NEW YORK--(BUSINESS WIRE)--BGC Group, Inc. (Nasdaq: BGC) today reported its financial results for the second quarter ended June 30, 2026. A complete financial results press release, including information about today’s conference call and BGC’s most recent dividend declaration, is available at http://ir.bgcg.com/, along with BGC’s earnings presentation and supplemental financial tables. About BGC Group, Inc. BGC Group, Inc. (Nasdaq: BGC) is a leading global marketplace, data, and financial techn...

IRVINE, Calif.--(BUSINESS WIRE)--Veritone, Inc. (NASDAQ: VERI), a leader in enterprise AI and data solutions, today announced the details of its second quarter 2026 financial results conference call. Veritone will hold a conference call on Thursday, August 13, 2026, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time), to discuss its results for the second quarter 2026, provide an update on the business and conduct a question-and-answer session. To participate, please join the conference call or...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to enzomenib (DSP-5336) for the treatment of patients with acute lymphoblastic leukemia (ALL). Enzomenib is an investigational, oral, small molecule inhibitor of the menin and lysine (K)-specific methyltransferase 2A (KMT2A) protein interaction, a key interaction in acute leukemia and other tumor cell proliferation and gro...

CINCINNATI--(BUSINESS WIRE)--As Comerica customers begin receiving information about their transition to Fifth Third (NYSE: FITB) many will gain access to banking products and services designed to help them save money, access funds sooner and enjoy greater flexibility in how they manage their finances. Beginning this week, customers are receiving personalized Welcome Packages that explain how their current Comerica accounts will transition to comparable Fifth Third products when the conversion...

CINCINNATI--(BUSINESS WIRE)--Resilience today announced it has expanded its strategic partnership with Eli Lilly and Company to increase U.S. production of critical medicines....

RESTON, Va. & LIVINGSTON, N.J.--(BUSINESS WIRE)--Responding to the rapidly growing need for secure artificial intelligence (AI) technology dedicated to the U.S. Intelligence Community (IC) and Department of War’s (DoW) unique requirements, Leidos (NYSE: LDOS), a leader in national security mission solutions, and CoreWeave (Nasdaq: CRWV), The Essential Cloud for AI™, are teaming up to provide secure, sovereign AI cloud services that can be used to help federal agencies build, train, deploy, and...

RALEIGH, N.C.--(BUSINESS WIRE)--Advance Auto Parts Announces Date for Second Quarter 2026 Earnings Release and Conference Call...

PALO ALTO, Calif., & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced the first patient was dosed in its Phase 2b clinical trial evaluating a potent, highly selective oral small molecule antagonist of MRGPRX2, EVO756, for the prophylactic treatment of migraine. "Initiating this migraine trial is an exciting mileston...